1Pincus T, Bergman MJ, Yazici Y, et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures[J]. Rheumatology, 2008,47 (3) : 345 - 349.
2PincusT, Segurado OG. Most visits of mostpatients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count[J]. Ann Rheum Dis, 2006, 65(6) :820- 822.
3Pincus T, Amara I, Segurado OG, et al. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials[J]. J Rheumatol, 2008, 35(2) :201 - 205.
4U. S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, FDA Center for Biologics Evaluation and Research, FDA Center for Devices and Radiological Health. Guidance for inductory; Patient-reported outcome measures: use in medical product development to support labeling claims:draft guidance[J]. Health Qual Life Outcome, 2006, (4) : 79.
5Kirwan J, Heiberg T, Hewlett S,et al. Outcomes from the Patient Perspective Workshop at OMERACT 6 [ J ]. J Rheumatol, 2003,30 (4) : 868 - 872.
6Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis progress at OMERACT 7[J]. J Rheumatol, 2005,32 (11 ) : 2250 - 2256.
7Pincus Theodore,Chung Cecilia,Segurado Oscar G,et al.An index of patient reported outcomes(PRO-Index)discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis[J].Journal of Rheumatology,2006,33 (11):2146-2152.
